ALNY vs DYN
ALNY: Alnylam is a pioneer in RNA interference (RNAi) therapeutics, using gene-silencing technology to treat rare genetic diseases and cardiovascular conditions. DYN: Dyne Therapeutics is a clinical-stage biotechnology company developing targeted muscle therapeutics for rare diseases using its proprietary FORCE platform.
Side-by-side fundamentals
| Metric | ALNY | DYN | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $205.52 | $25.18 | |
| Market cap as of 2026-08-03 | $27.5B | $4.7B | |
| P/E as of 2026-08-03 | 34.98 | n/a | |
| PEG as of 2026-08-03 | 0.75 | n/a | |
| Net margin as of 2026-08-03 | +16.8% | n/a | |
| Gross margin as of 2026-08-03 | +79.7% | n/a | |
| Operating margin as of 2026-08-03 | +19.9% | n/a | |
| ROE as of 2026-08-03 | +93.6% | -58.3% | ALNY higher |
| ROA as of 2026-08-03 | +15.8% | -46.8% | ALNY higher |
| Debt / equity as of 2026-08-03 | 2.02 | 0.18 | DYN lower |
| Revenue growth (YoY) as of 2026-08-03 | +95.1% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +53.0% | n/a | |
| Beta as of 2026-08-03 | 0.71 | 1.79 | |
| 1-year return as of 2026-07-31 close | -47.6% | +155.6% | DYN higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.